<DOC>
	<DOCNO>NCT00000980</DOCNO>
	<brief_summary>To determine safety effectiveness intravenous spiramycin patient AIDS-related cryptosporidial diarrhea . Spiramycin , macrolide antibiotic , study United States treatment cryptosporidial diarrhea . Some report suggest spiramycin useful improve symptom cryptosporidial diarrhea patient . Results one study , however , show significant difference spiramycin placebo ( inactive medication ) . A late study indicate absorption spiramycin significantly decrease food present . Thus , result trial may due poor absorption spiramycin .</brief_summary>
	<brief_title>A Study Spiramycin Treatment Patients With AIDS-Related Diarrhea</brief_title>
	<detailed_description>Spiramycin , macrolide antibiotic , study United States treatment cryptosporidial diarrhea . Some report suggest spiramycin useful improve symptom cryptosporidial diarrhea patient . Results one study , however , show significant difference spiramycin placebo ( inactive medication ) . A late study indicate absorption spiramycin significantly decrease food present . Thus , result trial may due poor absorption spiramycin . Patients observe 3 day establish baseline condition . They inform treatment period 21 day receive 15 day spiramycin 6 consecutive day placebo ; tell 6-day period receive placebo . All patient receive 15 day spiramycin . Patients favorable response treat high dose spiramycin additional 15 day . Responders either dose followed weekly 4 week . Should relapse occur , patient receive additional 15 day therapy , dose spiramycin initially produce response , follow reestablishment baseline 6 day placebo . Nonresponders higher dose take study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Cryptosporidiosis</mesh_term>
	<mesh_term>Spiramycin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Vitamin supplement . Zidovudine ( AZT ) patient previously take AZT . However , dose spiramycin delay dose AZT stabilize . The dose may decrease AZTassociated toxicity . Allowed diarrhea : Loperamide hydrochloride capsule ( 2 mg ) loperamide hydrochloride liquid ( 1 mg/5 ml ) . Allowed nausea : Sucralfate metoclopramide hydrochloride . Allowed vomiting : Prochlorperazine trimethobenzamide hydrochloride . Allowed prophylaxis Pneumocystis carinii pneumonia ( PCP ) : Aerosolized pentamidine . Patients must : A diagnosis AIDS accord CDC . Chronic diarrhea . Presence Cryptosporidium oocysts stool specimen . Patients legally authorize representative must sign informed consent form . Diet lactose free , maximum 7 g fat/day unlimited calorie intake . Patients require total parenteral nutrition also allow oral intake . Exclusion Criteria Coexisting Condition : Patients follow exclude : Grade 4 ( hematologic ) Grade 3 ( ) toxicity . Known sensitivity macrolide antibiotic . Presence diarrheacausing pathogen . Active opportunistic infection require systemic antimicrobial therapy . Toxicity grade accord NIAID toxicity scale adult . Concurrent Medication : Excluded : Other investigational drug . Cancer chemotherapy . Alpha interferon . Other immunomodulating agent . Other macrolide antibiotic . Trimethoprim / sulfamethoxazole . Ganciclovir . H2 blocker AL721 . Medications know cause gastrointestinal irritation alteration gastrointestinal motility absorption avoid possible . Zidovudine ( AZT ) therapy may initiate dose may increase study . Patients follow exclude : Grade 4 ( hematologic ) Grade 3 ( ) toxicity . Known sensitivity macrolide antibiotic . Presence diarrheacausing pathogen . Active opportunistic infection require systemic antimicrobial therapy . Toxicity grade accord NIAID toxicity scale adult . Prior Medication : Excluded within 7 day study entry : Investigational drug . Excluded within 14 day study entry : Cancer chemotherapy . Alpha interferon . Other immunomodulating agent . Other macrolide antibiotic . Trimethoprim / sulfamethoxazole . Ganciclovir .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 1990</verification_date>
	<keyword>Single-Blind Method</keyword>
	<keyword>Spiramycin</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Injections , Intravenous</keyword>
	<keyword>Cryptosporidiosis</keyword>
	<keyword>Diarrhea</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>